Colon cancer stands as a major cause of cancer-related deaths globally, necessitating enhanced diagnostic and therapeutic methods. The variance in patient responses highlights the urgent need for personalized treatment strategies. The study "Multi-omics profiling reveals cellular pathways and functions regulated by ALDH1B1 in colon cancer cells," linked to dataset GSE231706, advances our comprehension of colon cancer's molecular intricacies via ALDH1B1 suppression. This research, which utilizes novel biomarkers and genetic insights, is crucial for advancing personalized medicine by pinpointing specific molecular signatures, thus paving the way for customized treatments that promise to elevate survival rates and patient quality of life. Moreover, the use of the user-friendly, codeless platform g.nome® aims ease biologists ability to discover new targeted therapy pathways.

 

Future forecasts predict a surge in CRC cases to 3.2 million and deaths to 1.6 million by 2040, primarily in countries with a high Human Development Index (HDI), highlighting the need for improved preventive measures targeting modifiable risk factors to curb the anticipated growth in CRC morbidity and mortality 3.

This situation necessitates a reassessment of screening protocols to possibly include younger age brackets, along with a call for focused research to uncover the environmental, lifestyle, and genetic elements contributing to this increase. Adopting a holistic strategy could potentially reverse current trends and diminish the future CRC burden 4, 5. The enzyme Aldehyde dehydrogenase 1B1 (ALDH1B1) has attracted attention in colon cancer research due to its role in cancer stem cell biology and as a prospective therapeutic target. Its upregulation in colon cancer underscores its contribution to cancer stem cells' (CSCs) maintenance and survival, which play a role in tumor initiation, metastasis, chemotherapy resistance, and recurrence7,8. ALDH1B1's involvement in key signaling pathways like Wnt/β-catenin, Notch, and PI3K/Akt, crucial for CSC properties such as self-renewal, differentiation, and resistance, highlights its therapeutic potential9.

Recent endeavors to inhibit ALDH1B1 with small-molecule inhibitors offer new hope in battling colon cancer by undermining CSC support, thus impeding tumor progression and lessening the chance of treatment resistance and recurrence. This strategy exemplifies the ongoing pursuit of more efficacious colon cancer treatments, stressing the importance of targeted therapies that address the shortcomings of existing treatment options10. Investigating ALDH1B1's role and regulation in colon cancer progression and CSC dynamics is vital, as it will aid in developing precise treatments, potentially enhancing patient outcomes.

The integration of molecular profiling into the treatment of colorectal cancer (CRC) marks a significant shift towards personalized medicine, tailoring therapies to the genetic and molecular characteristics of an individual's tumor. The study's findings on the pivotal role of ALDH1B1 in CRC underscore the potential of targeted therapies, which could significantly improve patient outcomes by focusing on specific molecular pathways implicated in tumorigenesis and disease progression1,2.

Molecular profiling, including genomic sequencing and expression analysis of cancer cells, allows for the identification of unique biomarkers, such as overexpression of ALDH1B1, and mutation patterns that are critical for selecting the most effective treatment strategies3. By understanding the molecular landscape of a patient's tumor, clinicians can predict which therapies are likely to be most effective and which are likely to result in resistance, thereby avoiding unnecessary side effects and optimizing treatment efficacy.

For instance, the identification of mutations in signaling pathways modulated by ALDH1B1 can inform the use of small-molecule inhibitors specifically targeting these pathways, offering a more precise approach to therapy that is likely to yield better outcomes4. Similarly, molecular profiling can identify patients who would benefit from targeted therapies against specific pathways, such as the Wnt/β-catenin or PI3K/Akt pathways, which are involved in CRC stem cell maintenance and survival.

Furthermore, the personalized medicine approach extends beyond the selection of targeted therapies to include monitoring of disease progression and response to treatment through liquid biopsies, enabling real-time adjustments to therapy plans based on the molecular characteristics of circulating tumor DNA5.

The findings from studies focusing on the molecular underpinnings of CRC, particularly the role of ALDH1B1, highlight the critical importance of molecular profiling in developing personalized treatment strategies. This approach not only promises to enhance the effectiveness of CRC treatments but also to significantly improve patient outcomes by ensuring that therapies are tailored to the unique genetic makeup of each tumor.

 

Objectives

  • Accelerate Data Analysis with g.nome: Employ g.nome's codeless platform to expedite the analysis of dataset GSE231706, streamlining the identification of key molecular pathways and speeding up research progress.
  • Pathway Analysis of Colon Cancer: Utilize g.nome for in-depth analysis of ALDH1B1's role in colon cancer, aiming to uncover critical pathways for targeted treatment strategies.

 

Leveraging the g.nome platform, our study reevaluated data from "Multi-omics profiling reveals cellular pathways and functions regulated by ALDH1B1 in colon cancer cells," associated with dataset GSE231706, to deepen our understanding of colon cancer's molecular mechanisms. By focusing on the suppression of ALDH1B1, we identified critical molecular pathways that are essential for personalized cancer treatment strategies. This approach underscores the potential of g.nome in uncovering new therapeutic targets, emphasizing its role in the development of tailored treatments aimed at improving patient outcomes.



Results

 

Our gene set enrichment analysis (GSEA) illuminated several biological processes significantly enriched in the colorectal cancer (CRC) dataset, underscoring the complex interplay of genetic and molecular alterations in CRC pathobiology. The analysis revealed a spectrum of processes pivotal to cancer development and progression, including DNA replication and repair, cell cycle regulation, RNA processing, protein localization and transport, mitochondrial gene expression, and the ubiquitin-dependent protein catabolic process.

DNA Replication and Repair: A notable enrichment was observed in processes related to DNA replication and double-strand break repair, highlighting the critical role of genomic integrity in cancer. The dysregulation of DNA repair mechanisms, as indicated by the enrichment of genes involved in double-strand break repair and DNA replication, underscores the genomic instability characteristic of colorectal cancer. Similarly, the regulation of DNA repair processes was significantly enriched, suggesting a potential avenue for therapeutic intervention by targeting the DNA damage response pathway.

Cell Cycle Regulation: Our findings also emphasized the importance of cell cycle processes, including mitotic nuclear division, sister chromatid segregation, and chromosome segregation. The dysregulation of these processes, manifesting as uncontrolled cell proliferation, is a hallmark of cancer. The significant enrichment of genes within these categories highlights the potential for targeting cell cycle checkpoints and regulators as a strategy for cancer therapy.

RNA Processing: Alterations in RNA splicing, rRNA processing, and ncRNA processing were also significantly enriched, reflecting the emerging understanding of RNA processing's role in cancer. These processes are crucial for the post-transcriptional regulation of gene expression, and their dysregulation may contribute to the aberrant gene expression profiles observed in colorectal cancer.

In summary, our pathway analysis of the colorectal cancer dataset has identified several key biological processes that are significantly enriched and potentially contribute to the initiation, progression, and metastasis of colorectal cancer. These findings underscore the complexity of colorectal cancer pathogenesis and highlight potential targets for therapeutic intervention and biomarkers for disease detection and prognosis. Further investigation into the specific genes within these enriched categories will be crucial for elucidating their precise roles in colorectal cancer and translating these insights into clinical applications.



Conclusion

Through the integration of g.nome's analysis, we aim to make it easy to produce results that will be used to enhance the precision of CRC treatments by targeting specific pathways involved in tumor initiation, metastasis, and resistance. This approach not only promises to improve survival rates and quality of life for patients but also contributes to the broader mission of reducing the global burden of colorectal cancer by implementing targeted and personalized treatment strategies.

 

 

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
  2. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. doi: 10.1038/s41575-019-0189-8. Epub 2019 Aug 27. PMID: 31455888.
  3. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr;66(4):683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27. PMID: 26818619.
  4. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020 May;70(3):145-164. doi: 10.3322/caac.21601. Epub 2020 Mar 5. PMID: 32133645.
  5. Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018 Jul;68(4):250-281. doi: 10.3322/caac.21457. Epub 2018 May 30. PMID: 29846947.
  6. Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W, Jimeno A, Vasiliou V. ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/β-Catenin, Notch and PI3K/Akt Signaling Pathways. PLoS One. 2015 May 7;10(5):e0121648. doi: 10.1371/journal.pone.0121648. PMID: 25950950; PMCID: PMC4423958. 
  7. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011 May 1;10(9):1378-84. doi: 10.4161/cc.10.9.15486. Epub 2011 May 1. PMID: 21552008.
  8. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12. doi: 10.1073/pnas.0603806103. Epub 2006 Jul 20. PMID: 16857736; PMCID: PMC1544234.
  9. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012 Oct;30(10):2100-13. doi: 10.1002/stem.1193. PMID: 22887839; PMCID: PMC3448863.
  10. Feng Z, Hom ME, Bearrood TE, Rosenthal ZC, Fernández D, Ondrus AE, Gu Y, McCormick AK, Tomaske MG, Marshall CR, Kline T, Chen CH, Mochly-Rosen D, Kuo CJ, Chen JK. Targeting colorectal cancer with small-molecule inhibitors of ALDH1B1. Nat Chem Biol. 2022 Oct;18(10):1065-1075. doi: 10.1038/s41589-022-01048-w. Epub 2022 Jul 4. PMID: 35788181; PMCID: PMC9529790.